Bluebird Bio (NASDAQ: BLUE) Posing Strong Bearish Trend

BLUE is currently trading above its 50-day and 200-day simple moving averages (SMA), indicating a bullish trend. However, the 50-day SMA is below the 200-day SMA, forming a death cross pattern, which is a bearish signal.
The 20-day exponential moving average (EMA) is also above the current price, acting as a resistance level. A break above the 20-day EMA could signal a continuation of the uptrend, while a break below the 50-day SMA could signal a reversal of the trend.

Earnings and Revenue: The earnings per share (EPS) of BLUE is expected to decline by 37.50% in the current quarter (Dec 2023) and increase by 333.30% in the next quarter (Mar 2024). The EPS for the current year (2023) is estimated to be -$11.7, which is a 59.10% decrease from the previous year (2022). The EPS for the next year (2024) is projected to be -$8.6, which is an 26.50% increase from the current year2. The revenue of BLUE is expected to decrease by 3.10% in the current quarter (Dec 2023) and increase by 9.00% in the next quarter (Mar 2024). The revenue for the current year (2023) is estimated to be $289.2 million, which is a 0.80% decrease from the previous year (2022). The revenue for the next year (2024) is forecasted to be $313.6 million, which is a 8.40% increase from the current year.

The technical analysis of BLUE shows that the stock is in a mixed trend, with some bullish and bearish signals. The stock is also facing low volatility and uncertain momentum. The earnings and revenue estimates suggest that the company is going through a challenging period, but might recover in the future.